RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration ("FDA") approved INSPIRA ART100 system at one of Israel's renowned medical centers affiliated with the largest health care provider. A team of pioneeri

RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology. This breakthrough innovation is uniquely designed to oxygenate blood effectively without the trauma associated with conventional hollow fiber technologies. The in vivo testing achieved above 99% gas exchange target at a defined flow rate. The VORTX technology, slated for integration into Inspira's pipeline, including the INSPIRA ART500, aims to transform acute respiratory ca

RA'ANANA, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, April 15, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received payment from its U.S. distributor, Glo-Med Networks Inc. ("Glo-Med"), for a delivery of its INSPIRA™ ART100 systems, which are cleared by the U.S. Food & Drug Administration ("FDA"). The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical center, as previously announced. In addition

RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by expert physicians at Westchester Medical Center in New York State, marking the first real-world implementation of Inspira's innovative technology. During the life-support procedure, the INSPIRA ART100 effectively provided comprehensive heart and lung support

Inspira's innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA'ANANA, Israel, March 25, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary bypass procedures at one of New York's premier hospitals. We believe that this installation represents a significant milestone in the Company's deployment plan, as the Company nears the first

As FDA-cleared INSPIRA ART100 system begins deployment at top New York hospital amid $21B+ in recent medtech acquisitions including J&J's $13.1B Shockwave deal and Boston Scientific's $3.7B Axonics purchase, Company's innovative HYLA blood sensor achieves 96% accuracy in clinical trials as Inspira advances its flagship INSPIRA ART500 system targeting 20 million annual respiratory patients with AI technology Market News Alerts Reports: Inspira Technologies (NASDAQ:IINN)* is reported beginning deployment of its FDA-cleared INSPIRA ART100 system at a leading New York cardiothoracic program ranked among the top 15% nationally, marking a significant commercialization milestone in a sector exper

Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event RA'ANANA, Israel, March 19, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Gl

Inspira Technologies' remarkable 96% accuracy in HYLA blood sensor clinical trials positions the company to target both the $5.7 billion blood gas analyzer market and the $19 billion mechanical ventilation market; Strengthened by FDA-cleared ART100 already being deployed in U.S. hospitals and HYLA FDA submission on track for H2 2025; Company shifts focus to now accelerate development of flagship INSPIRA ART500 system, potentially transforming respiratory care for millions of ICU patients worldwide PESG Research releases an update following Inspira Technologies' (NASDAQ:IINN)* recent strategic developments and clinical achievements: Inspira has emerged as a potential disruptive force in res

Letter from the CEO / March 14, 2025 RA'ANANA, Israel, March 14, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (NASDAQ:IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is pleased to share this update to shareholders from its Chief Executive Officer, Director, and Co-founder, Mr. Dagi Ben Noon. Dear Valued Shareholders, We founded Inspira Technologies with a bold vision: to radically transform life-support for the millions of patients who each year face the harsh realities of mechanical ventilation. Today, I believe that the INSPIRA ART500 system we are developing s

RA'ANANA, Israel, March 13, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.  Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until September 8, 202

Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

20-F/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

144 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa

RA'ANANA, Israel, May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the Company's business targets, distribution agreements and next steps in a conference call to be held at 9:00am Eastern Time on Thursday, June 20, 2024. This follows the significant milestone of receiving FDA clearance for the INSPIRA™ ART100 system, as announced on May 28, 2024. Event Details: Date: Thursday, June 20, 2024 Time: 9:00 am Eastern Time Speaker: Joe Hayon, President, Director, and Co-Founder Attendance Info

FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented, "In 2023, we achieved significant progress in diversifying our business development to ensure continuous growth, reaching very important milestones that we believ

The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.RA'ANANA, Israel, March 4, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, p

RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone. The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024. To attend the conference call, please enter: link Inspira Technologies OXY B.H.N. Ltd. Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Re

ORLANDO, FL / ACCESSWIRE / May 5, 2023 / RedChip Companies will air new interviews with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) and Genius Group Limited (NYSE:GNS) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Inspira Technologies: https://www.redchip.com/assets/iinn_interview_accessGenius Group: https://www.geniusuinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experien

ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Interview Highlights: In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President, Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading medi

ORLANDO, FL / ACCESSWIRE / December 22, 2022 / RedChip Companies will air a new interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading m

Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.     Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated

RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the

Dr. Nir is a clinical strategy expert with market experience RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company. As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives. With an unwavering commitment to patient care, inn

RA'ANANA, Israel, Aug. 10, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company"), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced the appointment of Lior Amit, CPA, to the Company's board of directors. Mr. Amit has extensive business and go-to-market experience to further support Inspira's planned future deployment and market penetration of the Augmented Respiration Technology (ART) system. For more than 17 years, Mr. Amit served as the CFO of the BBR Saatchi & Saatchi advertising group in Israel, playing a vital role in the